Related references
Note: Only part of the references are listed.Bench to bedside: NK cells and control of metastasis
Yelena Krasnova et al.
CLINICAL IMMUNOLOGY (2017)
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
Arabella Young et al.
CANCER CELL (2016)
Immunosuppressive activities of adenosine in cancer
Bertrand Allard et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
CD73-adenosine: a next-generation target in immuno-oncology
David Allard et al.
IMMUNOTHERAPY (2016)
Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action
James C. Geoghegan et al.
MABS (2016)
A Metabolic immune Checkpoint: Adenosine in Tumor Microenvironment
Akio Ohta
FRONTIERS IN IMMUNOLOGY (2016)
Targeting CD73 in the tumor microenvironment with MEDI9447
Carl M. Hay et al.
ONCOIMMUNOLOGY (2016)
Neutrophils in cancer: neutral no more
Seth B. Coffelt et al.
NATURE REVIEWS CANCER (2016)
Targeting Cancer-Derived Adenosine: New Therapeutic Approaches
Arabella Young et al.
CANCER DISCOVERY (2014)
Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Bertrand Allard et al.
CLINICAL CANCER RESEARCH (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells
Mikkel G. Terp et al.
JOURNAL OF IMMUNOLOGY (2013)
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors
Paul A. Beavis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Neutrophils as effector cells for antibody-based immunotherapy of cancer
Marjolein van Egmond et al.
SEMINARS IN CANCER BIOLOGY (2013)
CD73-Deficient Mice Are Resistant to Carcinogenesis
John Stagg et al.
CANCER RESEARCH (2012)
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
John Stagg et al.
CANCER RESEARCH (2011)
Altered purinergic signaling in CD73-deficient mice inhibits tumor progression
Gennady G. Yegutkin et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice
Long Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
Fubin Li et al.
SCIENCE (2011)
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo
Falk Nimmerjahn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
RNA interference of ecto-5′-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion
Xiuling Zhi et al.
CLINICAL & EXPERIMENTAL METASTASIS (2007)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Share Paper
